Patents by Inventor Thomas Bayne

Thomas Bayne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SPORE-BASED PROBIOTIC COMPOSITION FOR REDUCTION OF DIETARY ENDOTOXEMIA AND RELATED METHODS
    Publication number: 20230049876
    Abstract: A method of treating metabolic endotoxemia comprising identifying a subject having post-prandial dietary endotoxemia and administering an effective amount of a spore-based probiotic. While any spore-based probiotic may be used, the probiotic supplement may comprise Bacillus indicus (HU36), Bacillus subtilis (HU58), Bacillus coagulans, Bacillus licheniformis, and Bacillus clausii. One or more of a level of blood endotoxin, triglyceride, post-prandial insulin, post-prandial ghrelin level, MCP-1, GM-CSF, IL-12p70, IL-13, IL-1beta, IL-4, IL-5, IL-6, IL-7, IL-8, and TNF-? is observed as being lower after spore-based probiotic supplementation when compared to placebo. At least one of post-prandial leptin and IL-10 is observed as being higher after spore-based probiotic supplementation when compared to placebo.
    Type: Application
    Filed: October 18, 2022
    Publication date: February 16, 2023
    Applicant: Novozymes A/S
    Inventors: Kiran Krishnan, Dale Kriz, Thomas Bayne
  • Spore-Based Probiotic Composition for Reduction of Dietary Endotoxemia and Related Methods
    Publication number: 20180289752
    Abstract: A method of treating metabolic endotoxemia comprising identifying a subject having post-prandial dietary endotoxemia and administering an effective amount of a spore-based probiotic. While any spore-based probiotic may be used, the probiotic supplement may comprise Bacillus indicus (HU36), Bacillus subtilis (HU58), Bacillus coagulans, Bacillus licheniformis, and Bacillus clausii. One or more of a level of blood endotoxin, triglyceride, post-prandial insulin, post-prandial ghrelin level, MCP-1, GM-CSF, IL-12p70, IL-13, IL-1beta, IL-4, IL-5, IL-6, IL-7, IL-8, and TNF-? is observed as being lower after spore-based probiotic supplementation when compared to placebo. At least one of post-prandial leptin and IL-10 is observed as being higher after spore-based probiotic supplementation when compared to placebo.
    Type: Application
    Filed: April 6, 2018
    Publication date: October 11, 2018
    Inventors: Kiran Krishnan, Dale Kriz, Thomas Bayne